Skip to main content

Credit Suisse Takes Teva Rating To Neutral In Third Upgrade Of Day

Credit Suisse analyst Vamil Divan upgraded earlier today Teva Pharmaceutical to Neutral from Underperform and raised his price target for the shares to $20.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.